<?xml version='1.0' encoding='utf-8'?>
<document id="29887518"><sentence text="Physiological and pharmacological characterization of the N1303K mutant CFTR." /><sentence text="N1303K, one of the common, severe disease-causing mutations in the CFTR gene, causes both defective biogenesis and gating abnormalities of the CFTR protein" /><sentence text=" The goals of the present study are to quantitatively assess the gating defects associated with the N1303K mutation and its pharmacological response to CFTR modulators including potentiators VX-770 and GLPG1837 and correctors VX-809, and VX-661" /><sentence text="" /><sentence text="Gating behavior and pharmacological responses to CFTR potentiators were assessed using patch-clamp technique in the excised, inside-out mode" /><sentence text=" We also examined the effects of GLPG1837, VX-770, VX-809 and VX-661 on N1303K-CFTR surface expression using Western blot analysis" /><sentence text="" /><sentence text="Like wild-type (WT) CFTR, N1303K-CFTR channels were activated by protein kinase A-dependent phosphorylation, but the open probability (Po) of phosphorylated N1303K-CFTR was extremely low (~0" /><sentence text="03 vs ~0" /><sentence text="45 in WT channels)" /><sentence text=" N1303K mutants showed abnormal responses to ATP analogs or mutations that disrupt ATP hydrolysis and/or dimerization of CFTR's two nucleotide-binding domains (NBDs)" /><sentence text=" However, the Po of N1303K-CFTR was dramatically increased by GLPG1837 (~17-fold) and VX-770 (~8-fold)" /><sentence text=" VX-809 or VX-661 enhanced N1303K-CFTR maturation by 2-3 fold, and co-treatment with GLPG1837 or VX-770 did not show any negative drug-drug interaction" /><sentence text="" /><sentence text="N1303K has a severe gating defect, reduced ATP-dependence and aberrant response to ATP analogs"><entity charOffset="83-86" id="DDI-PubMed.29887518.s15.e0" text="ATP" /><entity charOffset="43-45" id="DDI-PubMed.29887518.s15.e1" text="ATP" /><pair ddi="false" e1="DDI-PubMed.29887518.s15.e1" e2="DDI-PubMed.29887518.s15.e1" /><pair ddi="false" e1="DDI-PubMed.29887518.s15.e1" e2="DDI-PubMed.29887518.s15.e0" /></sentence><sentence text=" These results suggest a defective function of the NBDs in N1303K-CFTR" /><sentence text=" An improvement of channel function by GLPG1837 or VX-770 and an increase of Band C protein by VX-809 or VX-661 support a therapeutic strategy of combining CFTR potentiator and corrector for patients carrying the N1303K mutation" /><sentence text="" /></document>